AMENDMENTS TO THE CLAIMS

The following listing of claims replaces all prior versions and listings of claims in the application.

Listing of Claims

1. (currently amended) A pharmaceutical composition comprising a compound of the following general formula:



or a pharmaceutically acceptable salt thereof;

and a physiologically acceptable carrier, excipient or diluent;

wherein the pharmaceutical composition is suitable for human therapeutic administration; and

wherein:

X is OH, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is [[C_5-]]C_6 alkoxy, OCH_2Cyclopropyl, OCH_2Cyclopentyl, O-(2,2,3,3-tetrafluoro-cycloButyl), ~~phenoxy, substituted~~ phenoxy substituted with 4-nitrile, 4-methyl, 3-phenyl, 3-bromo, 3-isopropyl, 2-methyl, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 2,3,5-trifluoro, or (3-methyl,4-fluoro), ~~OCH_2CH_2OH,~~ OCH_2CHF_2, (5-indanyl)oxy, C_1, C_2, C_5, or C_6 alkylamino, (R) or (S)-sec-Butylamino, ~~C_5 or~~ C_6 cycloalkylamino, exo-norbornane amino, N-methyl-N-isoamylamino, phenylamino, phenylamino with either a methoxy substituent or a fluoro

substituent , a C_2 sulfone group, a C_7 alkyl group, a cyano group, a $CONH_2$ group, or 3,5-dimethylphenyl; or

X is H, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is *n*-hexyloxy.

2. (previously presented) A composition according to claim 1, wherein R_1 is phenoxy substituted with 4-nitrile, 4-methyl, 3-phenyl, 3-bromo, 3-isopropyl, 2-methyl, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 2,3,5-trifluoro, or (3-methyl,4-fluoro).

3. (currently amended) A composition according to claim 1, wherein the compound is a compound selected from the group consisting of compound numbers 2, 3, 5, 7-28, 30-33, and 35-40 ~~2-3 and 5-40~~ as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2Cyclopropyl
5	OH	O $CH_2CH_2CH_2CH_2CH_2CH_3$
~~6~~	~~OH~~	~~OPh~~
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph
11	OH	O-(3,4-F_2)Ph

Compound Number	X	R_1
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
14	OH	O-(2-Me)Ph
15	OH	O-(3-Br)Ph
16	OH	O-(4-Me)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
19	OH	$NHCH_3$
20	OH	$NHCH_2CH_3$
21	OH	$N(CH_3)_2$
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-Butyl
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
26	OH	NHPh
27	OH	NH-(4-MeO)Ph
28	OH	NH-(4-F)Ph
~~29~~	~~OH~~	~~NH-cyclopentyl~~
30	OH	NH-cyclohexyl
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl
33	OH	$SO_2CH_2CH_3$
~~34~~	~~OH~~	~~OCH_2CH_2OH~~
35	OH	O-(2,2,3,3-tetrafluoro-cycloButyl)
36	OH	$CH_2CH_2CH_2CH_2CH_2CH_2CH_3$
37	OH	3,5-Me_2-Phenyl

Compound Number	X	R_1
38	OH	CN
39	OH	$CONH_2$
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

4. (previously presented) A composition according to claim 3, wherein the compound is a compound selected from the group consisting of compound numbers 2, 3, 7-19, 22-25, 28, 31-33, and 35-40 as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2Cyclopropyl
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph
11	OH	O-(3,4-F_2)Ph
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
14	OH	O-(2-Me)Ph

Compound Number	X	R_1
15	OH	O-(3-Br)Ph
16	OH	O-(4-Me)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
19	OH	$NHCH_3$
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-Butyl
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
28	OH	NH-(4-F)Ph
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl
33	OH	$SO_2CH_2CH_3$
35	OH	O-(2,2,3,3-tetrafluoro-cycloButyl)
36	OH	$CH_2CH_2CH_2CH_2CH_2CH_2CH_3$
37	OH	3,5-Me_2-Phenyl
38	OH	CN
39	OH	$CONH_2$
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

5. (previously presented) A composition according to claim 3, wherein the compound is a compound selected from the group consisting of compound numbers 2, 3, 7-18, 22-25, 31-33, 35, 37 and 40 as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2Cyclopropyl
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph
11	OH	O-(3,4-F_2)Ph
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
14	OH	O-(2-Me)Ph
15	OH	O-(3-Br)Ph
16	OH	O-(4-Me)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-Butyl
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl

Compound Number	X	R_1
33	OH	$SO_2CH_2CH_3$
35	OH	O-(2,2,3,3-tetrafluoro-cycloButyl)
37	OH	3,5-Me_2-Phenyl
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

6-28 (cancelled)

29. (previously presented) A composition according to claim 3, wherein the compound is a compound selected from the group consisting of compound numbers 2, 3, 7-13, 15, 17, 18, 22-25, 31-33, 35, 37 and 40 as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2cyclopropyl
5	OH	O $CH_2CH_2CH_2CH_2CH_2CH_3$
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph

Compound Number	X	R_1
11	OH	O-(3,4-F_2)Ph
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
15	OH	O-(3-Br)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-butyl
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl
33	OH	$SO_2CH_2CH_3$
35	OH	O-(2,2,3,3-tetrafluoro-cyclobutyl)
37	OH	3,5-Me_2-Phenyl
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

30. (withdrawn) A method of preventing, treating, or ameliorating a pathological condition that can be prevented or improved by agonism of adenosine A2A receptors, which comprises administering a composition as defined in claim 1 to a subject in need of such prevention, treatment, or amelioration.

31 (cancelled)

32. (withdrawn) A method of preventing, treating, or ameliorating pain which comprises administering a composition as defined in claim 1 to a subject in need of such prevention, treatment, or amelioration.

33. (withdrawn) A method of preventing, treating, or ameliorating ischaemic pain which comprises administering a composition as defined in claim 1 to a subject in need of such prevention, treatment, or amelioration.

34. (withdrawn) A method according to claim 33 for the prevention, treatment, or amelioration of ischaemic pain associated with coronary artery disease, peripheral artery disease, left ventricular hypertrophy, essential hypertension, acute hypertensive emergency, cardiomyopathy, heart insufficiency, exercise tolerance, chronic heart failure, arrhythmia, cardiac dysrhythmia, syncopy, arteriosclerosis, mild chronic heart failure, angina pectoris, Prinzmetal's (variant) angina, stable angina, exercise induced angina, cardiac bypass reocclusion, intermittent claudication (arteriosclerosis oblitterens), arteritis, diastolic dysfunction, systolic dysfunction, atherosclerosis, post ischaemia/reperfusion injury, diabetes (Types I or II), thromboembolisms, haemorrhagic accidents, or neuropathic or inflammatory pain arising from hypoxia-induced nerve cell damage.

35. (withdrawn) A method of prevention, treatment, or amelioration of inflammation, which comprises administering a composition as defined in claim 1 to a subject in need of such prevention, treatment, or amelioration.

36. (withdrawn) A method according to claim 35 for the prevention, treatment, or amelioration of inflammation caused by or associated with: cancer (such as leukemias, lymphomas, carcinomas, colon cancer, breast cancer, lung cancer, pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma, hepatic, lung, breast, and prostate metastases, etc.); auto-immune disease (such as organ transplant rejection, lupus erythematosus, graft v. host rejection, allograft rejections, multiple sclerosis, rheumatoid arthritis, type I diabetes mellitus including the destruction of pancreatic islets leading to diabetes and the inflammatory consequences of diabetes); autoimmune damage (including multiple sclerosis, Guillam Barre Syndrome, myasthenia gravis); obesity; cardiovascular conditions associated with poor tissue perfusion and inflammation (such as atheromas, atherosclerosis, stroke, ischaemia-reperfusion injury, claudication,

congestive heart failure, vasculitis, haemorrhagic shock, vasospasm following subarachnoid haemorrhage, vasospasm following cerebrovascular accident, pleuritis, pericarditis, the cardiovascular complications of diabetes); ischaemia-reperfusion injury, ischaemia and associated inflammation, restenosis following angioplasty and inflammatory aneurysms; epilepsy, neurodegeneration (including Alzheimer's Disease), muscle fatigue or muscle cramp (particularly athletes' cramp), arthritis (such as rheumatoid arthritis, osteoarthritis, rheumatoid spondylitis, gouty arthritis), fibrosis (for example of the lung, skin and liver), sepsis, septic shock, encephalitis, infectious arthritis, Jarisch-Herxheimer reaction, shingles, toxic shock, cerebral malaria, Lyme's disease, endotoxic shock, gram negative shock, haemorrhagic shock, hepatitis (arising both from tissue damage or viral infection), deep vein thrombosis, gout; conditions associated with breathing difficulties (e.g. chronic obstructive pulmonary disease, impeded and obstructed airways, bronchoconstriction, pulmonary vasoconstriction, impeded respiration, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, cystic fibrosis, pulmonary hypertension, pulmonary vasoconstriction, emphysema, bronchial allergy and/or inflammation, asthma, hay fever, rhinitis, vernal conjunctivitis and adult respiratory distress syndrome); conditions associated with inflammation of the skin (including psoriasis, eczema, ulcers, contact dermatitis); conditions associated with inflammation of the bowel (including Crohn's disease, ulcerative colitis and pyresis, irritable bowel syndrome, inflammatory bowel disease); HIV (particularly HIV infection), bacterial meningitis, TNF-enhanced HIV replication, TNF inhibition of AZT and DDI activity, osteoporosis and other bone resorption diseases, osteoarthritis, rheumatoid arthritis, infertility from endometriosis, fever and myalgia due to infection, cachexia secondary to cancer, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), AIDS related complex (ARC), keloid formation, scar tissue formation, adverse effects from amphotericin B treatment, adverse effects from interleukin-2 treatment, adverse effects from OKT3 treatment, or adverse effects from GM-CSF treatment, and other conditions mediated by excessive anti-inflammatory cell (including neutrophil, eosinophil, macrophage and T-cell) activity.

37. (withdrawn) A method of preventing, treating, or ameliorating macro or micro vascular complications of type 1 and 2 diabetes, retinopathy, nephropathy, autonomic neuropathy, or blood vessel damage caused by ischaemia or atherosclerosis which comprises administering a composition as defined in claim 1 to a subject in need of such prevention, treatment, or amelioration.

38. (withdrawn) A method of slowing the progression of arthropathy, which comprises administering a composition as defined in claim 1 as a disease-modifying antirheumatic drug (DMARD) to a subject in need thereof.

39. (withdrawn) A method according to claim 38, for slowing the progression of rheumatoid arthritis.

40. (withdrawn) A method according to claim 30, wherein the composition is administered at a dose that gives rise to a peak plasma concentration of the compound that is less than the EC50 value of the compound at adenosine receptors at pH 7.4.

41. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that results in a peak plasma concentration of the compound in the subject that is one ten thousandth to one half of the lowest EC50 value of the compound at adenosine receptors.

42. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one half of the lowest EC50 value of the compound at adenosine receptors.

43. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that results in a peak plasma concentration of the compound in the subject that is one ten thousandth to one half of the lowest Kd value of the compound at adenosine receptors.

44. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one half of the lowest Kd value of the compound at adenosine receptors.

45. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that is one ten thousandth to one half of the minimum amount of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the compound is administered.

46. (withdrawn) A method according to claim 30, wherein the composition is administered at a dose that is one thousandth to one half of the minimum dose of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the dose is to be administered.

47. (withdrawn) A method according to claim 46, wherein the dose is one hundredth to one half of the minimum dose that gives rise to the side effects.

48. (withdrawn) A method according to claim 30, wherein the composition is administered to the subject in an amount that results in a plasma concentration of the compound in the subject being maintained for more than one hour at one ten thousandth to one half of the minimum plasma concentration of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the compound is administered.

49. (withdrawn) A method according to claim 30, wherein the composition is administered at a dose that results in a plasma concentration of the compound that is maintained for more than one hour between one hundredth and one half of the minimum dose of the compound that gives rise to bradycardia, hypotension or tachycardia side effects in animals of the same species as the subject to which the compound is to be administered.

50. (withdrawn) A method according to claim 30, wherein the composition is administered in an amount which provides a dose of the compound of less than 0.4mg/kg.

51. (withdrawn) A method according to claim 30, wherein the composition is administered in an amount which provides a dose of the compound of 0.001 to 0.4mg/kg.

52. (withdrawn) A method according to claim 30, wherein the composition is administered in an amount which provides a dose of the compound of at least 0.003mg/kg.

53. (withdrawn) A method according to claim 30, wherein the composition is administered in an amount which provides a dose of the compound of 0.01 to 0.1mg/kg.

54. (withdrawn) A method according to claim 30, wherein the composition is administered orally, parenterally, sublingually, transdermally, intrathecally, transmucosally, intravenously, intramuscularly, subcutaneously, topically, or by inhaling.

55. (withdrawn) A method according to claim 30, wherein the composition is administered at a frequency of 2 or 3 times per day.

56. (withdrawn) A method according to claim 30, wherein the subject is a human subject.

57. (cancelled)

58. (currently amended) A pharmaceutical composition according to claim 1, wherein the composition is in unit dose form and comprises ~~comprising~~ up to 500mg of the [[a]] compound or pharmaceutically acceptable salt thereof, ~~as defined in claim 1, excluding~~ wherein the compound is other than 2-phenylamino adenosine~~, and a physiologically acceptable carrier, excipient, or diluent~~.

59. (currently amended) A pharmaceutical composition according to claim 1, wherein the composition is in unit dose form and comprises ~~comprising~~ up to 500mg of the [[a]] compound or pharmaceutically acceptable salt thereof, ~~as defined in claim 1~~ together

with an NSAID or a DMARD~~, and a physiologically acceptable carrier, excipient, or diluent~~.

60-76 (cancelled)

77. (currently amended) A compound of the following general formula:



or a pharmaceutically acceptable salt thereof;

wherein:

X is OH, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is C_6 alkoxy, OCH_2cyclopropyl, OCH_2cyclopentyl, O-(2,2,3,3-tetrafluoro-cyclobutyl), OCH_2CHF_2, (5-indanyl)oxy, C_1, C_2, C_5, or C_6 alkylamino, (R) or (S)-sec-butylamino, ~~C_5 cycloalkylamino,~~ exo-norbornane amino, N-methyl-N-isoamylamino, ~~phenylamino with a fluoro substituent,~~ a C_2 sulfone group, a C_7 alkyl group, a cyano group, ~~a $CONH_2$ group,~~ or 3,5-dimethylphenyl; or

X is H, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is *n*-hexyloxy.

78. (currently amended) A compound selected from the group consisting of compound numbers 2, 3, 5, 7-25, ~~28, 29,~~ 31-33, ~~and~~ 35-38 and 40 as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2cyclopropyl
5	OH	O $CH_2CH_2CH_2CH_2CH_2CH_3$
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph
11	OH	O-(3,4-F_2)Ph
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
14	OH	O-(2-Me)Ph
15	OH	O-(3-Br)Ph
16	OH	O-(4-Me)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
19	OH	$NHCH_3$
20	OH	$NHCH_2CH_3$
21	OH	$N(CH_3)_2$
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-butyl

Compound Number	X	R_1
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
~~28~~	~~OH~~	~~NH-(4-F)Ph~~
~~29~~	~~OH~~	~~NH-cyclopentyl~~
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl
33	OH	$SO_2CH_2CH_3$
35	OH	O-(2,2,3,3-tetrafluoro-cyclobutyl)
36	OH	$CH_2CH_2CH_2CH_2CH_2CH_2CH_3$
37	OH	3,5-Me_2-Phenyl
38	OH	CN
~~39~~	~~OH~~	~~$CONH_2$~~
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

79. (currently amended) A compound according to claim 78 selected from the group consisting of compound numbers 2, 3, 5, 7-13, 15, 17-25, ~~28, 29,~~ 31-33, ~~and~~ 35-38 and 40 as defined below, or a pharmaceutically acceptable salt of such a compound:



Compound Number	X	R_1
2	OH	OCH_2CHF_2
3	OH	OCH_2cyclopropyl
5	OH	O $CH_2CH_2CH_2CH_2CH_2CH_3$
7	OH	O-(4-cyano)Ph
8	OH	O-(3-Ph)Ph
9	OH	O-(2,5-F_2)Ph
10	OH	O-(2,4-F_2)Ph
11	OH	O-(3,4-F_2)Ph
12	OH	O-(2,3,5-F_3)Ph
13	OH	O-(3-Me, 4-F)Ph
15	OH	O-(3-Br)Ph
17	OH	5-indanyloxy
18	OH	O-(3-$CH(CH_3)_2$)Ph
19	OH	$NHCH_3$
20	OH	$NHCH_2CH_3$
21	OH	$N(CH_3)_2$
22	OH	NH-(R)-sec-Butyl
23	OH	NH-(S)-sec-butyl
24	OH	$NHCH_2CH_2CH_2CH_2CH_2CH_3$
25	OH	NH-exo-norbornane
~~28~~	~~OH~~	~~NH-(4-F)Ph~~
~~29~~	~~OH~~	~~NH-cyclopentyl~~
31	OH	$N(CH_3)CH_2CH_2CH(CH_3)_2$
32	OH	OCH_2cyclopentyl
33	OH	$SO_2CH_2CH_3$
35	OH	O-(2,2,3,3-tetrafluoro-cyclobutyl)

Compound Number	X	R_1
36	OH	$CH_2CH_2CH_2CH_2CH_2CH_2CH_3$
37	OH	3,5-Me_2-Phenyl
38	OH	CN
~~39~~	~~OH~~	~~$CONH_2$~~
40	H	O $CH_2CH_2CH_2CH_2CH_2CH_3$

80. (currently amended) An oral dosage form comprising in said oral dosage form a composition comprising a compound of the following general formula:



or a pharmaceutically acceptable salt thereof;

and a physiologically acceptable carrier, excipient or diluent; and

wherein:

X is OH, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is [[C_5-]]C_6 alkoxy, OCH_2cyclopropyl, OCH_2cyclopentyl, O-(2,2,3,3-tetrafluoro-cyclobutyl), ~~phenoxy, substituted~~ phenoxy substituted with 4-nitrile, 4-methyl, 3-phenyl, 3-bromo, 3-isopropyl, 2-methyl, 2,4-difluoro, 2,5-difluoro, 3,4-difluoro, 2,3,5-trifluoro, or (3-methyl,4-fluoro), ~~OCH_2CH_2OH,~~ or OCH_2CHF_2, (5-indanyl)oxy, C_1, C_2, C_5, or C_6 alkylamino, (R) or (S)-sec-butylamino, ~~C_5 or~~ C_6 cycloalkylamino, exo-norbornane amino, N-methyl-N-isoamylamino, phenylamino, phenylamino with either methoxy or fluoro substituents, a

C_2 sulfone group, a C_7 alkyl group, a cyano group, a $CONH_2$ group, or 3,5-dimethylphenyl; or

X is H, R_2 is NH_2, R_5 is CH_2OH, R_6 is H, and R_1 is *n*-hexyloxy.

81. (previously presented) An oral dosage form according to claim 80, wherein the dosage form is a solid oral dosage form.

82. (previously presented) An oral dosage form according to claim 80, wherein the dosage form is a form selected from the group consisting of a tablet and a capsule.

83. (previously presented) An oral dosage form according to claim 80, wherein the dosage form is suitable for human administration.

84. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that gives rise to a peak plasma concentration of the compound that is less than the EC_{50} value of the compound at adenosine receptors at pH 7.4 following administration of the dosage form to a human.

85. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that results in a peak plasma concentration of the compound that is one ten thousandth to one half of the lowest EC_{50} value of the compound at adenosine receptors at pH 7.4 following administration of the dosage form to a human.

86. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that results in a plasma concentration of the compound being maintained for more than one hour that is one ten thousandth to one half of the lowest EC50 value of the compound at adenosine receptors at pH 7.4 following administration of the dosage form to a human.

87. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that results in a peak plasma

concentration of the compound that is one ten thousandth to one half of the lowest Kd of the compound at adenosine receptors at pH 7.4 following administration of the dosage form to a human.

88. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that results in a plasma concentration of the compound being maintained for more than one hour that is one ten thousandth to one half of the lowest EC50 value of the compound at adenosine receptors at pH 7.4 following administration of the dosage form to a human.

89. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that is one ten thousandth to one half of the minimum amount of the compound that gives rise to bradycardia, hypotension or tachycardia side effects following administration of the dosage form to a human.

90. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that is one thousandth to one half of the minimum amount of the compound that gives rise to bradycardia, hypotension or tachycardia side effects following administration of the dosage form to a human.

91. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the dosage form at a dose that is one hundredth to one half of the minimum amount of the compound that gives rise to bradycardia, hypotension or tachycardia side effects following administration of the dosage form to a human.

92. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the oral dosage form in an amount of less than 28mg.

93. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the oral dosage form in an amount of 0.07 to 28mg.

94. (previously presented) An oral dosage form according to claim 80, wherein the compound is present in the oral dosage form in an amount of 0.7 to 7mg.